Latest News

Lenalidomide May Overcome Rituximab Resistance in B-Cell Lymphomas

Lenalidomide May Overcome Rituximab Resistance in B-Cell Lymphomas

The combination of lenalidomide and rituximab overcomes prior rituximab resistance in patients with indolent B-cell and mantle cell lymphomas, a recent study published in the journal Clinical Cancer Research has shown.

Sunitinib May Be Acceptable First Line Treatment for Metastatic Renal Cell Carcinoma

Sunitinib May Be Acceptable First Line Treatment for Metastatic Renal Cell Carcinoma

Sunitinib represents an acceptable option in first line treatment for metastatic papillary renal cell carcinoma (mPRCC).

Minimal Benefit with Bortezomib, Dexamethasone as Maintenance Therapy for Multiple Myeloma

Minimal Benefit with Bortezomib, Dexamethasone as Maintenance Therapy for Multiple Myeloma

Addition of dexamethasone to bortezomib for the treatment of relapsed multiple myeloma as ongoing maintenance therapy has minimal benefit.

Vorinostat May Not Improve Survival in Mesothelioma

Vorinostat May Not Improve Survival in Mesothelioma

Vorinostat as second- or third-line therapy may not improve overall survival in advanced malignant pleural mesothelioma.

High Fish Intake Linked to Survival After Breast Cancer

High Fish Intake Linked to Survival After Breast Cancer

High intake of fish and long-chain ω-3 polyunsaturated fatty acids (PUFAs) is associated with reduced all-cause mortality after breast cancer.

New, Less Aggresssive Guidelines for Pancreatic Cysts

New, Less Aggresssive Guidelines for Pancreatic Cysts

New, less aggressive guidelines have been developed for management of pancreatic cysts.

Lower Lung, Colorectal Cancer Risk with High Fitness Levels in Midlife Men

Lower Lung, Colorectal Cancer Risk with High Fitness Levels in Midlife Men

Fit middle-aged men appear less likely to develop lung and colorectal cancer in later life than their out-of-shape peers.

Three Alcoholic Drinks Per Day Raises Liver Cancer Risk

Three Alcoholic Drinks Per Day Raises Liver Cancer Risk

People who have three or more alcoholic drinks per day could be raising their odds for liver cancer.

BTD Regimen May Be Viable Salvage Option for Multiple Myeloma

BTD Regimen May Be Viable Salvage Option for Multiple Myeloma

Bendamustine plus thalidomide and dexamethasone may be a viable salvage option for the treatment of double-relapsed/refractory multiple myeloma.

Adjusting Starting Dose of Lenalidomide for Renal Function May Not Compromise Efficacy

Adjusting Starting Dose of Lenalidomide for Renal Function May Not Compromise Efficacy

Adjusting the starting dose of lenalidomide according to renal function did not compromise the efficacy or safety of lenalidomide.

Early Initiation of Palliative Care Improves 1-Year Survival

Early Initiation of Palliative Care Improves 1-Year Survival

Early initiation of concurrent palliative oncology care improved 1-year survival compared with delayed initiation.

Biomarker Panel Shown to Be Surrogate for Survival in Prostate Cancer

Biomarker Panel Shown to Be Surrogate for Survival in Prostate Cancer

A biomarker panel was shown to be a surrogate for survival in patients with metastatic castration-resistant prostate cancer (mCRPC).

Intraperitoneal Chemotherapy Improves Survival in Ovarian Cancer

Intraperitoneal Chemotherapy Improves Survival in Ovarian Cancer

Intraperitoneal (IP) as opposed to intravenous (IV) chemotherapy is associated with better survival in patients with advanced ovarian cancer.

Patients Expect More Information About Radiation Testing

Patients Expect More Information About Radiation Testing

There is a considerable gap between patient expectations and current practices for information relating to radiation use.

In Non-Small Cell Lung Cancer, Pulmonologist Management Beneficial

In Non-Small Cell Lung Cancer, Pulmonologist Management Beneficial

For non-small-cell lung cancer (NSCLC), pulmonologist management is positively associated with rates of stage-specific treatment.

Nivolumab May Be Safe, Effective for Previously Treated Kidney Cancer

Nivolumab May Be Safe, Effective for Previously Treated Kidney Cancer

Nivolumab may be safe and effective in patients with advanced treatment-refractory renal cell carcinoma (RCC).

Tumor-Directed T Cells for HER2-Positive Sarcoma

Tumor-Directed T Cells for HER2-Positive Sarcoma

HER2-specific T cells can persist for 6 weeks without evident toxicities in patients with HER2-positive sarcoma.

Stress Management After Breast Cancer Surgery Has Lasting Benefit

Stress Management After Breast Cancer Surgery Has Lasting Benefit

Cognitive-behavioral stress management (CBSM) delivered after breast cancer surgery is associated with long-term psychological benefits.

Nivolumab Safer, More Effective Than Chemo for Advanced Melanoma

Nivolumab Safer, More Effective Than Chemo for Advanced Melanoma

Nivolumab led to a greater proportion of patients with advanced melanoma achieving an objective response and with fewer adverse events.

Doxorubicin Plus Trabectedin May Be Effective for Uterine, Soft-Tissue Leiomyosarcoma

Doxorubicin Plus Trabectedin May Be Effective for Uterine, Soft-Tissue Leiomyosarcoma

Doxorubicin plus trabectedin have activity as first-line treatment for uterine leiomyosarcoma and soft-tissue leiomyosarcoma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs